Haploidentical Hematopoietic Stem Cell Transplantation Versus Umbilical Cord Blood Transplantation in Hematologic Malignancies: A Systematic Review and Meta-Analysis

Ran Wu and Liyuan Ma

Abstract
Haploidentical hematopoietic stem cell transplantation (Haplo-SCT) and umbilical cord blood transplantation (UCBT) are two important alternatives when a matched sibling donor is unavailable. Several studies have reported inconsistent clinical outcomes comparing Haplo-SCT and UCBT. Therefore, it is necessary to synthesize the existing evidence regarding outcomes of stem cell transplantations comparing Haplo-SCT with UCBT. We searched article titles that compared transplantation with Haplo-SCT and UCBT in MEDLINE (PubMed), Cochrane library, and EMBASE database. To compare clinical outcomes between Haplo-SCT and UCBT, we performed a meta-analysis of 12 studies and reported the pooled odds ratios (ORs) of 6 end points including overall survival (OS), progression-free survival (PFS), nonrelapse mortality (NRM), relapse rate (RR), acute graft-versus-host disease (aGVHD), and chronic graft-versus-host disease (cGVHD). We found that Haplo-SCT was associated with a significantly superior OS (pooled OR of 0.74, 95% confidence interval [CI] 0.68 to 0.80) and PFS (0.77, 95% CI 0.72 to 0.83), as well as a lower NRM (0.72, 95% CI 0.64 to 0.80) and aGVHD (0.87, 95% CI 0.77 to 0.98) compared to the UCBT group. We also found a significantly increased risk of cGVHD in Haplo-SCT group (1.40, 95% CI 1.22 to 1.62). In terms of RR, Haplo-SCT was comparable to UCBT (0.91, 95% CI 0.79 to 1.05). Results of this meta-analysis demonstrate that Haplo-SCT results in better clinical outcomes compared to UCBT in terms of OS, PFS, TRM, and aGVHD, but is inferior to UCBT in terms of increased cGVHD risk. Further prospective comparisons between Haplo-SCT and UCBT are needed.

Keywords
haploidentical hematopoietic stem cell transplantation, umbilical cord blood transplantation, hematologic malignancies, meta-analysis

Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a well-established curative treatment for hematologic malignancies. Human leukocyte antigen (HLA)-matched sibling donor (MRD) is the first choice for allo-HSCT. Unfortunately, only about 30% of patients have an MRD available. In the past, haploidentical hematopoietic stem cell transplantation (Haplo-SCT) was not routinely used for fear of significant GVHD or graft rejection. The alternative strategy was pursuing an HLA-matched unrelated donor (MUD). Unfortunately, even with large donor banks worldwide, many patients are still unable to find a suitable MUD. Through advances in basic and clinical research, alternative donor platforms using Haplo-SCT or umbilical cord blood transplantation (UCBT) have been developed in the past few decades to solve the obstacle of donor unavailability for allo-HSCT.

1 Department of Hematology, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Department of Hematology, Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China

Submitted: June 14, 2020. Revised: September 11, 2020. Accepted: September 18, 2020.

Corresponding Author:
Liyuan Ma, Department of Hematology, Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, 639# Zhizaoju Road, Shanghai 200011, China.
Email: docmly@126.com
Up to now, two most popular T-cell-repleted Haplo-SCT protocols have been widely performed worldwide\textsuperscript{10–12}. The GIAC Haplo-SCT protocol developed by the Beijing group integrates granulocyte colony-stimulating factor primed grafts, intensive immunosuppression, anti-thymocyte globulin (ATG), and combined peripheral blood stem cell and bone marrow\textsuperscript{13–15}. Post-transplantation cyclophosphamide (PTCy) Haplo-SCT protocol was initiated by the Baltimore group\textsuperscript{7,16}. It has been documented that the GIAC Haplo-SCT protocol produced similar outcome to that of MRD for patients with acute leukemia\textsuperscript{14,17}. PTCy prevents GVHD by directly inhibiting alloreactive T cells, while preserving memory or regulatory T cells\textsuperscript{18}. PTCy protocol was associated with high engraftment rates and low rates of infections, nonrelapse mortality (NRM), severe acute graft-versus-host disease (aGVHD), and chronic graft-versus-host disease (cGVHD)\textsuperscript{19}. UCBT offers several benefits such as immediate graft availability, less strict HLA matching requirements, reduced incidence of cGVHD, and favorable graft-versus-leukemia (GVL) effects\textsuperscript{8,9,15}. Experienced UCBT centers reported comparable progression-free survival (PFS) and overall survival (OS) rates to MUD SCT\textsuperscript{20}. The main disadvantages for UCBT include higher graft failure rate, delayed engraftment and immune reconstitution, higher rates of opportunistic infections, relatively high rate of NRM, and lack of donor lymphocyte infusion in the event of relapse post transplantation\textsuperscript{21}.

Currently, under condition of no MRD available, the best alternative graft source, MUD, umbilical cord blood, or Haplo donors, remains controversial. In order to optimize donor selection algorithm, it is imperative to compare the clinical outcome of various stem cell sources. Herein, we aim to synthesize the recent evidence regarding outcomes of Haplo-SCT, as compared with UCBT for patients with hematologic malignancies. Our primary endpoints are OS, PFS, NRM, RR, aGVHD, and cGVHD.

**Materials and Methods**

**Search Strategy**

We searched the MEDLINE (PubMed), Embase, and Cochrane Registry of Controlled Trials databases (updated November 2019), using the following terms: haploidentical transplant/transplantation, umbilical cord blood transplant/transplantation, alternative graft source. The PubMed and Embase searches were restricted to humans and English language articles. We limited the publication type to comparative clinical studies. The titles, abstracts, and reference lists were screened to identify eligible studies, and clearly nonrelevant articles were discarded. In addition, the reference lists of relevant studies and reviews were reviewed to identify other potentially eligible studies\textsuperscript{22,23}.

**Study Selection and Data Extraction**

We included all published clinical studies of regarding Haplo-SCT and UCBT with survival outcomes. Studies were included if they fulfilled the following criteria: patients with hematologic malignancies; prospective or retrospective studies reporting on more than 10 patients undergoing Haplo-SCT and UCBT in each group; comparison with transplants from Haplo-SCT and UCBT as graft type. Two authors independently extracted the data from the chosen studies. The following information was extracted from the included studies: the name of the first author, year of publication, study design, GVHD prophylaxis, type of disease, type of transplant, number of participants, type of conditioning regimen, length of follow-up, and so on. Main end points for data synthesis were OS, PFS, NRM, relapse rate (RR), grade II to IV aGVHD, and overall cGVHD.

**Data Synthesis**

The meta-analysis was performed using STATA (version 12.0) software. The threshold of significance was \( P < 0.05 \). Egger’s test, Begg’s test, and funnel plots were used to investigate publication bias. \( F \) statistic was used to assess statistical heterogeneity, with \( F > 50\% \) set as the cutoff to indicate significant result heterogeneity. Hazard ratios (HRs) and 95\% confidence intervals (CIs) were collected from each study. When HRs and CIs were not given in a paper, data were calculated by the method of Tierney\textsuperscript{24}. A forest plot with combined odds ratio (OR) (with 95\% CIs) for OS, PFS, NRM, RR, aGVHD, and cGVHD benefits of Haplo-SCT versus UCBT was constructed using fixed-effects analysis\textsuperscript{22,23}.

**Results**

**General Description of Included Studies**

The initial search yielded 902 articles; 865 were excluded from the title and abstract review, which were not pertaining to our research. A total of 37 articles underwent full-length review; 23 of them were excluded because they only evaluated patients receiving either Haplo-SCT, UCBT, or combined Haplo-SCT and UCBT, nonhematologic cancers, and lack of direct comparison results; 2 articles were excluded due to insufficient data. The final analysis included 12 studies including 2 prospective clinical studies\textsuperscript{25,26} and 10 retrospective cohort studies\textsuperscript{27–36}. This included 2,793 patients who underwent Haplo-SCT (1,432 patients) or UCBT (1,361 patients). Table 1 describes the characteristics of the 12 included studies. The median sample size was 173 patients (range 45 to 526). Two hundred seventy-seven patients were pediatric patients. Diseases that underwent Haplo-SCT or UCBT were mainly acute leukemia, other hematologic malignancies including myelodysplastic syndrome, chronic myelogenous leukemia, and lymphoma.
| Study (year) | n | Age, median (range), years | Male, % | Disease | Conditioning | Cord blood unit s/d, % | Graft source for Haplo | GVHD prophylaxis | F/U, median (range), months |
|-------------|---|---------------------------|---------|---------|--------------|----------------------|-----------------------|-------------------|---------------------|
| Brunstein (2011) |  |  |  |  |  |  |  |  |  |
| Haplo | 50 | 48 (7-70) | NR | ALL, AML, HL, NHL | RIC 100% | BM 100% | PTCy+Tac+MMF | 11.9 (3.4-14.7) |
| CBT | 50 | 58 (16-69) | NR | ALL, AML, HL, NHL | RIC 100% | 0/100 | CSA+MMF | 12 (1.8-13.7) |
| Sanz J (2019) |  |  |  |  |  |  |  |  |  |
| Haplo | 22 | 41 (18-55) | 68 | AML, ALL, MDS, CML | MAC 100% | BM 100% | PTCy+CSA+MMF | 32 (13-46) |
| CBT | 23 | 45 (24-54) | 48 | AML, ALL, MDS, CML | MAC 100% | 100/0 | CSA+Pred | 32 (21-46) |
| El-Cheikh (2015) |  |  |  |  |  |  |  |  |  |
| Haplo | 69 | 44 (19-68) | 57 | various | NMAC 100% | BM 72%, PB 28% | PTCy+CSA+MMF | 24 (1-103) |
| CBT | 81 | 47 (18-66) | 57 | various | NMAC 100% | 21/79 | CSA+MMF | 14 (1-52) |
| Mo XD (2016) |  |  |  |  |  |  |  |  |  |
| Haplo | 65 | 10 (3-14) | 51 | ALL | MAC 100% | BM+PB 100% | ATG+CSA+MTX+MMF | 20.7 (1.3-58.3) |
| CBT | 64 | 9 (2-14) | 65 | ALL | MAC 100% | 100/0 | CSA+MMF | 14.5 (0.7-58.4) |
| Mo XD (2014) |  |  |  |  |  |  |  |  |  |
| Haplo | 111 | 15 (4-18) | 70 | Various | MAC 100% | BM+PB 100% | ATG+CSA+MTX+MMF | 36 (1.2-134.4) |
| CBT | 37 | 9 (2-18) | 62 | Various | MAC 100% | 100/0 | CSA+Methylpred | 39.6 (1.2-141.6) |
| Rasiola (2014) |  |  |  |  |  |  |  |  |  |
| Haplo | 92 | 45 (17-69) | NR | Various | MAC 77%, RIC 23% | BM 100% | PTCy+CSA+MMF | 19.2 (0.37-52.6) |
| CBT | 105 | 40 (18-64) | NR | Various | MAC 83%, RIC 17% | 100/0 | CSA+MMF | 12.4 (0.07-89.1) |
| Robin (2019) |  |  |  |  |  |  |  |  |  |
| Haplo | 222 | 61 (51-66) | 55 | MDS | MAC 30%, RIC 70% | BM 45%, PB 55% | PTCy | 24 |
| CBT | 168 | 57 (45-64) | 58 | MDS | NA | NA | NA | 37 |
| Kanate (2019) |  |  |  |  |  |  |  |  |  |
| Haplo | 49 | 55 (20-74) | 57 | Various | MAC 35%, RIC/NMA 65% | BM 45% PB 55% | PTCy+CNi+MMF | 31 |
| CBT | 37 | 44 (21-63) | 51 | Various | MAC 22%, RIC/NMA 77% | 0/100 | CNi+MMF | 48 |
| Versluis (2017) |  |  |  |  |  |  |  |  |  |
| Haplo | 193 | 51 (18-75) | 57 | AML | MAC 54% RIC 46% | BM 52% PB 48% | PTCy/ATG | 22 (1-120) |
| CBT | 333 | 48 (18-72) | 44 | AML | MAC 44% RIC 45% | s/d | CNi+MMF+ATG | 24 (2-214) |
| Giannotti (2018) |  |  |  |  |  |  |  |  |  |
| Haplo | 186 | 44.3 (18.5=66.1) | 45.7 | AML | MAC 100% | BM 80% PB 20% | PTCy+CNi+MMF | 22.07 (0-96.3) |
| CBT | 147 | 42.6 (18-67.9) | 44.2 | AML | MAC 100% | 100/0 | CNi+MMF | 24.42 (0-83.1) |
| Deteix (2019) |  |  |  |  |  |  |  |  |  |
| Haplo | 127 | 55 (20-73) | 56 | AML | MAC 33% RIC 67% | BM 32% PB 68% | PTCy+CNi+MMF | 18 |
| CBT | 153 | 49 (15-73) | 51 | AML | MAC 45% RIC 55% | s/d | CNi+MMF | 18 |
| Ruggeri (2019) |  |  |  |  |  |  |  |  |  |
| Haplo | 246 | 60 (18-76) | 69 | sAML | MAC 41% RIC 59% | NA | PTCy | 16.9 (3-101) |
| CBT | 166 | 56 (19-73) | 58 | sAML | MAC 34% RIC 66% | s/d | CNi+MMF | 24.3 (3-112) |

ATG: anti-thymocyte globulin; BM: bone marrow; CNi: calcineurin inhibitor; CSA: cyclosporin; MAC: myelo-ablative-conditioning; Methylpred: methylprednisolone; MMF: mycophenolate mofitil; MTX: methotrexate; NMA: nonmyeloablative; PB: peripheral blood; pred: prednisone; PTCy: post-transplantation cyclophosphamide; RIC: reduced intensity conditioning; Tac: tacrolimus.
Majority of patients received myelo-ablative-conditioning (MAC) regimen. Patients in UCBT group received either single-unit cord blood or double-unit cord blood infusion. Graft source for Haplo-SCT includes bone marrow, mobilized peripheral blood, or both. Protocol for Haplo-SCT is T cell repletion (unmanipulated), which includes GIAC protocol or PTCy protocol. GVHD prophylaxis for Haplo-SCT includes ATG based or PTCy based combined with calcineurin inhibitor plus mycophenolate mofitil. GVHD prophylaxis for UCBT mainly combined calcineurin inhibitor with mycophenolate mofitil.

**Meta-Analysis Results**

Prior to meta-analysis, we checked for publication bias using Egger’s test, Begg’s test, and funnel plot method. The results showed that all studies investigating end points including OS, PFS, NRM, RR, aGVHD, and cGVHD were not statistically significant ($P = 0.1, 0.06, 0.48, 0.5, 0.37$, and $0.5$ for OS, PFS, NRM, RR, aGVHD, and cGVHD, respectively, by Egger’s test). The funnel plot also suggested that there was no publication bias for these six end points.

OS data were evaluable for 12 studies, and the interstudy heterogeneity was nonsignificant ($P = 0.233$), with $I^2 = 21.4\%$. In a fixed-effects forest plot, the combined OR for OS was pooled OR of $0.74$, $95\%$ CI $0.68-0.80$, indicating that Haplo-SCT could increase OS of patients compared with UCBT (Fig. 1). PFS data were available for 11 studies, and the interstudy heterogeneity was nonsignificant ($P = 0.38$), with $I^2 = 5.8\%$. In a fixed-effects forest plot, the combined OR for PFS was pooled OR of $0.77$, $95\%$ CI $0.72$ to $0.83$, suggesting that Haplo-SCT could increase PFS of patients compared with UCBT (Fig. 2). NRM data were evaluable for 12 studies, and the interstudy heterogeneity was significant ($P = 0.007$), with $I^2 = 57.2\%$. In a fixed-effects forest plot, the combined OR for NRM was pooled OR of $0.72$, $95\%$ CI $0.64$ to $0.80$, suggesting that Haplo-SCT could reduce NRM of patients compared with UCBT (Fig. 3). RR data were available for 12 studies, and the interstudy heterogeneity was nonsignificant ($P = 0.1$), with $I^2 = 37.2\%$. In a fixed-effects forest plot, the combined OR for RR was pooled OR of $0.91$, $95\%$ CI $0.79$ to $1.05$, indicating that Haplo-SCT was associated with similar RR outcome compared with UCBT (Fig. 4). aGVHD data were available for 11 studies, and the interstudy heterogeneity was significant ($P = 0.006$), with $I^2 = 59.3\%$. In a fixed-effects forest plot, the combined OR for aGVHD was pooled OR of $0.87$, $95\%$ CI $0.77$ to $0.98$, suggesting that Haplo-SCT could reduce aGVHD of patients compared with UCBT (Fig. 5). Chronic GVHD data were available for 11 studies, and the
Figure 2. Meta-analysis result of disease-free survival.
CI: confidence interval; OR: odds ratio; haplo-SCT: haploidentical hematopoietic stem cell transplantation; UCBT: umbilical cord blood transplantation.

Figure 3. Meta-analysis result of nonrelapse mortality.
CI: confidence interval; OR: odds ratio; haplo-SCT: haploidentical hematopoietic stem cell transplantation; UCBT: umbilical cord blood transplantation.
Figure 4. Meta-analysis result of relapse rate.
CI: confidence interval; OR: odds ratio; haplo-SCT: haploidentical hematopoietic stem cell transplantation; UCBT: umbilical cord blood transplantation.

Figure 5. Meta-analysis result of acute GVHD (II-IV).
aGVHD: acute graft-versus-host disease; CI: confidence interval; OR: odds ratio; haplo-SCT: haploidentical hematopoietic stem cell transplantation; UCBT: umbilical cord blood transplantation.
interstudy heterogeneity was significant ($P = 0.001$), with $I^2 = 83.6\%$. In a fixed-effects forest plot, the combined OR for cGVHD was pooled OR of 1.40, 95% CI 1.22 to 1.62, indicating that Haplo-SCT could increase cGVHD of patients compared with UCBT (Fig. 6). There are 10 studies associated with PTCy-based Haplo-SCT, while the other 2 studies from China were ATG-based. We analyzed outcomes of Haplo-SCT compared with CBT according to PTCy- or ATG-based regimen in subgroup meta-analysis (Table 2 and Fig. 7), which demonstrated that Haplo-SCT resulted in better clinical outcomes compared to UCBT in terms of OS, PFS, and TRM, but was inferior to UCBT in terms of increased cGVHD risk both in PTCy-based and ATG-based protocols.

**Discussion**

For patients with hematologic malignancies requiring allo-HSCT but who lack an MRD, the best choice of alternative stem cell source remains unclear. The different types of alternative donors have disparate advantages and drawbacks in terms of rapidity of obtaining stem cells, efficacy, and tolerability, and the criteria or algorithm for selecting one type of alternative donor over another are not well established\(^27\). In general, comparing Haplo-SCT and UCBT outcome in the absence of randomized prospective studies is difficult. There are so far only two prospective studies comparing Haplo-SCT and UCBT\(^25,26\). One study from the blood and marrow transplantation clinical trials network conducted two parallel multicenter phase 2 trials for individuals with leukemia or lymphoma who do not have suitable related donor. Reduced-intensity conditioning was used with either unrelated double umbilical cord blood (dUCB) or HLA-

![Figure 6. Meta-analysis result of chronic GVHD.](image)

cGVHD: chronic graft-versus-host disease; CI: confidence interval; OR: odds ratio; haplo-SCT: haploidentical hematopoietic stem cell transplantation; UCBT: umbilical cord blood transplantation.

### Table 2. Outcomes of Haplo-SCT Compared With CBT According to PTCy- or ATG-based Regimen.

| End point | GVHD prophylaxis | PTCy based | ATG based |
|-----------|------------------|------------|-----------|
|           | Pooled OR (95%CI) | $I^2$ | Pooled OR (95%CI) | $I^2$ |
| OS        | 0.741 (0.684-0.802) | 35.5 | 0.725 (0.507-1.038) | 0 |
| PFS       | 0.776 (0.720-0.837) | 22 | 0.756 (0.551-1.038) | 0 |
| NRM       | 0.721 (0.640-0.812) | 64 | 0.635 (0.402-1.004) | 0 |
| RR        | 0.919 (0.792-1.066) | 43 | 0.829 (0.472-1.456) | 38 |
| aGVHD     | 0.776 (0.677-0.890) | 0 | 1.629 (1.200-2.210) | 74 |
| cGVHD     | 1.180 (1.015-1.372) | 74 | 4.627 (2.769-7.734) | 79 |

aGVHD: acute graft-versus-host disease; ATG: anti-thymocyte globulin; CBT: cord blood transplantation; cGVHD: chronic graft-versus-host disease; CI: confidence interval; haplo-SCT: haploidentical hematopoietic stem cell transplantation; NRM: nonrelapse mortality; OR: odds ratio; OS: overall survival; PFS: progression-free survival; PTCy: post-transplantation cyclophosphamide; RR: relapse rate.
haploidentical related donor bone marrow (Haplo-marrow) transplantation. The 1-year probabilities of OS and PFS were 54% and 46%, respectively, after dUCB transplantation and 62% and 48%, respectively, after Haplo-marrow transplantation. The 100-day cumulative incidence of grade II-IV aGVHD was 40% after dUCB and 32% after Haplo-marrow transplantation. The 1-year cumulative incidences of NRM and RR after dUCB transplantation were 24% and 31%, respectively, with corresponding results of 7% and 45%, respectively, after Haplo-marrow transplantation. Another study compared the outcomes of single-unit UCBT and unmanipulated Haplo-SCT with PTCy in adults with hematologic malignancies. All patients received an MAC regimen. Twenty-three underwent UCBT and 22 underwent Haplo-HSCT. Rates of aGVHD grade II-IV or grade III-IV, overall cGVHD, and extensive cGVHD in the UCBT and Haplo-SCT arms were 43% versus 36%, 9% versus 9%, 66% versus 43%, and 41% versus 23%, respectively. Two-year NRM and relapse in the two arms were 52% versus 23% and 17% versus 23%, respectively. Two-year DFS, OS, and GVHD/RFS in the two arms were 30% versus 54%, 35% versus 59%, and 17% versus 40%, respectively, indicating that in the context of an MAC regimen, Haplo-SCT with PTCy provides improved outcomes compared with ATG-containing single-unit UCBT. A retrospective single-institutional study by Raiola et al revealed that despite having more patients older than 50 (40% versus 23%) and with advanced disease (58% versus 41%), Haplo SCT using PTCy and bone marrow had superior 3-year NRM (18% versus 35%) and 4-year OS (52% versus 34%) than single-unit UCBT. The Acute Leukemia Working Party of EBMT analyzed more than 1,000 patients undergoing UCBT or Haplo-SCT and found similar relapse, NRM, and leukemia-free survival rates between the two groups. But high heterogeneity between different groups exists in this study, as the UCBT group had a higher complete remission rate at the time of SCT and less patients with poor cytoge-netic risk ALL. Up to now, there is only one meta-analysis conducted by Poonsombudlert K et al, which compared clinical

![Figure 7. Subgroup meta-analysis result of overall survival of Haplo-SCT compared with CBT according to PTCy- or ATG-based regimen.](image-url)
outcomes of patients who underwent Haplo-SCT or UCBT. The authors found a significantly decreased risk of aGVHD and relapse in the PTCy-haplo group compared to the UCBT group, and a significantly increased rate of cGVHD and OS. In contrast, in our current meta-analysis, we demonstrated that Haplo-SCT had better clinical outcomes compared to the UCBT in terms of OS, PFS, NRM, and aGVHD, but was inferior to UCBT in terms of increased cGVHD risk. Though these two meta-analysis results both demonstrated reduced aGVHD and increased cGVHD incidence in Haplo-SCT cohort, our meta-analysis result showed somewhat discrepancy with that of Poonsombudlert. We speculated that the underlying reason might be that (1) 12 studies were included in our analysis, but only 7 studies in their analysis; (2) only PTCy-based studies were included in their analysis, but both GIAC- and PTCy-based studies were included in our analysis; (3) 2 studies associated with pediatric patients were excluded in their analysis; (4) 2 studies with high intergroup heterogeneity or obvious publication bias was excluded from our analysis. In our meta-analysis, we found reduced aGVHD incidence in Haplo-SCT cohort. It is believed that PTCy selectively depletes the alloreactive T cells while preserving the non-alloreactive T cells, thus preventing against aGVHD while preserving the GVT effect. Recent findings suggest that PTCy may not fully eliminate alloreactive T cells. Rather, PTCy may induce functional impairment of CD4+ and CD8+ alloreactive T cells, thereby preventing new donor T cells from causing GVHD. NRM is one of the main complications influencing the outcomes of allo-HSCT, and in our meta-analysis, we found that NRM rate was lower in Haplo-SCT cohort, which was concurrent with other researches, while NRM of UCBT was relatively high due to delayed engraftment, slow immune reconstitution, and high rates of opportunistic infections. This low rate of NRM in Haplo-SCT was associated with superior OS and PFS in our meta-analysis result. As for relapse, our result showed no significant difference between Haplo-SCT and UCBT. It was documented that PTCy Haplo-SCT has relatively higher RR when using non-myeloablative conditioning regimen, while comparable RR was found with MAC regimen. In addition, UCBT can reduce RR in those high-risk acute leukemia patients. In our results, we did not find increased relapse rate in Haplo-SCT cohort or decreased relapse rate in UCBT cohort, and we did not perform subgroup analysis such as MAC versus non-myeloablative, complete remission versus non complete remission at transplant, which was a limitation of our work. In regard to cGVHD, many previous studies have shown that the rate of cGVHD is significantly lower in UCBT versus other types of graft source, which perhaps that naive fetal stem cells from umbilical cord are naturally less exposed to foreign antigen, thus resulting in less alloreactivity. Finally, we performed subgroup meta-analysis (Table 2 and Fig. 7) comparing Haplo-SCT with CBT according to PTCy- or ATG-based regimen, which further demonstrated that Haplo-SCT resulted in better clinical outcomes compared to UCBT in terms of OS, PFS, and TRM, but was inferior to UCBT in terms of increased cGVHD risk both in PTCy-based and ATG-based protocols.

Our study has several limitations: (1) most of the studies included were retrospective clinical trials, and lacking randomized controlled prospective clinical trials could possibly influence the objectivity and accuracy of meta-analysis; (2) our meta-analysis is limited by the heterogeneity between different studies, which originates from various indications for transplant, adult patients and pediatric patients, pretransplant comorbidities, disease status at transplant, conditioning regimen, and GVHD prophylaxis strategy. Subgroup analysis for factors such as prospective studies and retrospective studies, different diseases, adult and pediatric patients, disease status at transplant, and conditioning regimen should be performed. We found only two prospective studies, and two pediatric patient–associated studies were included in our meta-analysis. Furthermore, some studies were lacking in detailed information or outcomes regarding different disease types, disease status at transplant, and conditioning regimen, making it difficult to do subgroup analysis. (3) Different follow-up duration in different studies might influence the meta-analysis result, which is a common concern in all meta-analyses.

Conclusion

Results of this meta-analysis demonstrates that Haplo-SCT gives better clinical outcomes compared to the UCBT in terms of NRM and aGVHD, and while inferior to UCBT in terms of increased cGVHD risk, the OS and PFS are still superior over UCBT. Further large-scale, multicenter, prospective, controlled trials are needed to investigate the long-term outcomes of Haplo-SCT versus UCBT, which will provide unequivocal evidence for doctors to select the best alternative graft source.

Ethical Approval
Ethical approval is not applicable to this study.

Statement of Human and Animal Rights
This article does not contain any studies with human or animal subjects.

Statement of Informed Consent
Not applicable because this study did not directly involve human subjects.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.
ORCID iD
Liyuan Ma https://orcid.org/0000-0003-1589-7300

References
1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357(15):1472–1475.
2. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
3. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, Hartzman R, Rizzo JD, Horowitz M, Confer D, Maiers M. HLA match likelihoods for hematopoietic stem cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339–348.
4. Morin-Zorman S, Loiseau P, Taupin JL, Caillat-Zucman S. Donor-specific anti-hla antibodies in allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7:307.
5. Kanakry CG, de Lima MJ, Luznik L. Alternative donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Semin Hematol. 2015;52(3):232–242.
6. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, Chen H, Liu DH, Gao ZY, Chen YH, Xu LP, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107(8):3065–3073.
7. Luznik L, O’Donnell PV, Symons HI, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650.
8. Eapen M, Rocha V, Saz G, Scaradavou A, Zhang MJ, Arcese W, Sirvent A, Champlin RE, Chao N, Gee AP, Isola L, et al. Effect of graft source on unrelated donor haemopoietic stem cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11(7):653–660.
9. Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, Witherspoon R, Mielcarek M, Deeg JH, Sorror M, Dahlberg A, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375(10):944–953.
10. Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13(2):132.
11. Ikegame K, Yoshida T, Yoshihara S, Daimon T, Shimizu H, Maeda Y, Ueda Y, Kaida K, Ishii S, Taniguchi K, Okada M, et al. Unmanipulated haploidentical reduced-intensity stem cell transplantation using fludarabine, busulfan, low-dose antithymocyte globulin, and steroids for patients in non-complete remission or at high risk of relapse: a prospective multicenter phase ii study in Japan. Biol Blood Marrow Transplant. 2015;21(8):1495–1505.
12. Ikegame K, Kawakami M, Yamagami T, Maeda H, Onishi K, Taniguchi Y, Fujioka T, Masuda T, Kawase I, Ogawa H. HLA-haploidentical nonmyeloablative stem cell transplantation: induction to tolerance without passing through mixed chimerism. Clin Lab Haematol. 2005;27(2):139–141.
13. Huang XJ, Chang YJ. Unmanipulated HLA-mismatched/haploidentical blood and marrow hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(2):197–204.
14. Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, Fan ZP, Wu DP, Huang XJ. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125(25):3956–3962.
15. Liu JH, Kanakry CG, Luznik L. Have haploidentical transplants replaced umbilical cord transplants for acute leukemias? Curr Opin Hematol. 2018;25(2):103–111.
16. Bashey A, Zhang X, Jackson K, Brown S, Ridgeway M, Solh M, Morris LE, Holland HK, Solomon SR. Comparison of outcomes of hematopoietic cell transplants from t-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and hla-identical sibling donors: a multivariable analysis including disease risk index. Biol Blood Marrow Transplant. 2016;22(1):125–133.
17. Han LJ, Wang Y, Fan ZP, Huang F, Zhou J, Fu YW, Qu H, Xuan L, Xu N, Ye JY, Bian ZL, et al. Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission. Br J Haematol. 2017;179(1):120–130.
18. Kanakry CG, Ganguly S, Zahurak M, Bolanos-Meade J, Thobum C, Perkins B, Fuchs EJ, Jones RJ, Hess AD, Luznik L. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5(211):211ra157.
19. Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010;47(1-3):65–77.
20. Ponce DM, Hilden P, Devlin SM, Maloy M, Lubin M, Castro-Malaspina H, Dahi P, Hsu K, Jakubowski AA, Kernan NA, Koehne G, et al. High disease-free survival with enhanced protection against relapse after double-unit cord blood transplantation when compared with t cell-depleted unrelated donor transplantation in patients with acute leukemia and chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2015;21(11):1985–1993.
21. Barker JN, Kurtzberg J, Ballen K, Boo M, Brunstein C, Cutler C, Horwitz M, Milano F, Olson A, Spellman S, Wagner JE, et al. Optimal practices in unrelated donor cord blood transplantation: a phase ii study in Japan. Biol Blood Marrow Transplant. 2015;21(8):1495–1505.
transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2017;23(6):882–896.

22. Poonsombudlert K, Kewcharoen J, Prueksapraong C, Limpruttidham N. Post transplant cyclophosphamide based haplo-identical transplant versus umbilical cord blood transplant; a meta-analysis. Jpn J Clin Oncol. 2019;49(10):924–931.

23. Li Z, Liu Y, Wang Q, Chen L, Ma L, Hao S. Autologous stem cell transplantation is a viable postremission therapy for intermediate-risk acute myeloid leukemia in first complete remission in the absence of a matched identical sibling: a meta-analysis. Acta Haematol. 2019;141(3):164–175.

24. Tierney JF, Stewart LA, Gherdsi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(1):16.

25. Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, Jagasia MH, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282–288.

26. Sanz J, Montoro J, Solano C, Valcárcel D, Sampol A, Ferrá C, Parody R, Lorenzo I, Montesinos P, Orti G, Hernández-Boluda JC, et al. Prospective randomized study comparing myeloablative unrelated umbilical cord blood transplantation versus hla-haploidentical related stem cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant. 2020;26(2):358–366.

27. Deteix C, Mesnil F, Furst S, Milipied N, Yakoub-Agha I, Fegueux N, Latour RP, Mohty M, Chevallier P, Labussière Wallet H, Huynh A, et al. Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor. Bone Marrow Transplant. 2020;55(4):749–757.

28. El-Cheikh J, Crociolo R, Furst S, Bramanti S, Sarina B, Granata A, Vai A, Lemarie C, Faucher C, Mohty B, Harbi S, et al. Unrelated cord blood compared with haploidentical grafts in patients with hematologic malignancies. Cancer. 2015;121(11):1809–1816.

29. Giannotti F, Labopin M, Shouval R, Sanz J, Arcese W, Angelucci E, Sierra J, Santasusana JR, Santarone S, Benedetto B, Rambaldi A, et al. Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiopeta, busulfan, and fludarabine. J Hematol Oncol. 2018;11(1):110.

30. Kanate AS, Szabo A, Raj RV, Bower K, Grulke R, Shah N, Ross KG, Cumpton A, Craig M, Pasquini MC, Shah N, et al. Comparison of graft acquisition and early direct charges of haploidentical related donor transplantation versus umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2019;25(7):1456–1464.

31. Raiola AM, Dominietto A, di Grazia C, Lamparelli T, Gualandi F, Ibatici A, Bregante S, Van Lint MT, Varaldo R, Ghiso A, Gobbi M, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant. 2014;20(10):1573–1579.

32. Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, Angelucci E, Stölzel F, Potter V, Yakoub-Agha I, Koc Y, et al. HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. Biol Blood Marrow Transplant. 2019;25(1):114–120.

33. Ruggeri A, Labopin M, Savani B, Paviglianiti A, Blaise D, Volt F, Ciceri F, Bacigalupo A, Tischer J, Chevallier P, Koc Y, et al. Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. Bone Marrow Transplant. 2019;54(12):1987–1994.

34. Versluis J, Labopin M, Ruggeri A, Socie G, Wu D, Volin L, Blaise D, Milipied N, Craddock C, Yakoub-Agha I, Maertens J, et al. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Adv. 2017;1(7):477–485.

35. Mo XD, Zhao XY, Liu DH, Chen YH, Xu LP, Zhang XH, Chen H, Han W, Wang Y, Wang FR, Wang JZ, et al. Umbilical cord blood transplantation and unmanipulated haploidentical hematopoietic SCT for pediatric hematologic malignancies. Bone Marrow Transplant. 2014;49(8):1070–1075.

36. Mo XD, Tang BL, Zhang XC, Xu LP, Zhu XY, Wang Y, Liu HL, Yan CH, Chu XD, Chen H, et al. Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia. Int J Cancer. 2016;139(9):2106–2115.

37. Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A, Blaise D, Bosi A, Huang H, Karakasis D, Koc Y, et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia. 2015;29(9):1891–1900.

38. Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 2019;129(6):2357–2373.

39. McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolanos-Meade J, Rosner GL, Kanakry CG, Perika K, Symons HJ, Brodsky RA, Gladstone DE, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125(19):3024–3031.

40. Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignancies following a myeloablative...
conditioning: an update. Bone Marrow Transplant. 2015; 50(Suppl 2):S37–S39.

42. Gutman JA, Ross K, Smith C, Myint H, Lee CK, Salit R, Milano F, Delaney C, Gao D, Pollyea DA. Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation. Bone Marrow Transplant. 2016;51(12):1588–1593.

43. Berglund S, Magalhaes I, Gaballa A, Vanherberghen B, Uhlin M. Advances in umbilical cord blood cell therapy: the present and the future. Expert Opin Biol Ther. 2017;17(6):691–699.